CLINICAL SIGNIFICANCE OF NATRIURETIC PEPTIDES (review)
PDF

Keywords

diabetes mellitus 2 type, heart failure, metabolic syndrome, natriuretic peptides.

Abstract

Natriuretic peptides are widely known for their protective effects against the development of metabolic syndrome and cardiovascular disease. The important role of determining the levels of natriuretic peptides in the diagnosis, assessment of severity, prognosis and effectiveness of treatment of heart failure has been proven in many studies and noted in clinical guidelines worldwide. Visceral obesity reduces the production and action of natriuretic peptides, increasing the risk of heart failure and  diabetes mellitus 2 type. Metabolic syndrome is present in 60% of patients with chronic heart failure, most of its components contribute to the development and progression of chronic heart failure and include obesity, hypertension, dyslipidemia, insulin resistance, impaired glucose tolerance. The prevalence of metabolic syndrome in the general population is 34% and is constantly increasing due to unhealthy diet, sedentary lifestyle and chronic stress. The prevalence of chronic heart failure is increasing rapidly in all industrialized countries, affecting 2% of adults and 10% of the elderly. Therefore, the problem of early diagnosis and treatment of metabolic syndrome and chronic heart failure is very relevant nowadays. The review focuses on the pathophysiological relationships between natriuretic peptides, heart failure and metabolic syndrome, and the approaches to the correction of natriuretic peptides’ metabolism.

https://doi.org/10.35339/ic.9.1.5-13
PDF

References

Bajaj, N.S., Patel, N., Prabhu, S.D., Arora, G., & Wang, T.J. (2018). Effect of NT-proBNP–Guided Therapy on All-Cause Mortality in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol, 27, 71(8), 951‒952.

Brunner-La Rocca, H., & Sanders-van Wijk, S. (2019). Natriuretic Peptides in Chronic Heart Failure. Card Fail Rev, 5(1), 44–49.

Immaculate, N., Walter, M., Higgins, C., & Li, C. (2021). Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart FailureOnt Health Technol Assess Ser., 21(2), 1-125.

Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., & Casey, D.E. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology, 70, 6.

Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C. et al. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice European Heart Journal, 37, 2315–2381.

Barrett-Connor, E. (2013). The Rancho Bernardo Study: 40 years studying why women have less heart disease than men and how diabetes modifies women’s usual cardiac protection.

Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., John, M. et al. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37, 2999–3058.

Brunner-La Rocca, H., Kaye, D., Woods, R., Hastings, J., & Esler, M. (2001). Effects of intravenous brain na-triuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol, 37, 5, 1221‒1227.

Januzzi, J.J., Camargo, C.A., Anwaruddin, S., Baggish, A.L., & Chen, A.A. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol, 15, 95(8), 948‒954.

Januzzi, J.J., Chen-Tournoux, A.A., Christenson, R.H., Doros, G., & Hollander, J.E. (2018). N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. J Am Coll Cardiol., 20, 71(11), 1191‒1200.

Kerkelä, R., & Ulvila, J. (2015). Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Met-abolic Events. Journal of the American Heart Association, 4, 10.

Maisel, A., Duran, J., & Wettersten, N. (2018). Natriuretic Peptides in Heart Failure Atrial and B-type Natriu-retic Peptides. Heart Failure Clin, 14, 13–25.

Meems, L., & Burnett, J. (2016). Innovative Therapeutics Designer Natriuretic Peptides. JACC: Basic to trans-lational science, 1, 7.

Thawabi, M., Hawatmeh, A., Studyvin, S., Habib, H., & Shamoon, F. (2017). Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovasc Diagn Ther, 7, 4, 359–366.

Willeit, P., Kaptoge, S., Welsh, P., Butterworth, A.S., & Chowdhury, R. (2016). Natriuretic peptides and in-tegrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endo-crinol, 4, 10, 840‒849.

Maisel, A.S., & Daniels, L.B. (2012). Breathing Not Properly 10 Years Later: What We Have Learned and What We Still Need to Learn. Journal of the American College of Cardiology, 60, 4, 277‒282.

Januzzi, J.J., Camargo, C.A., Anwaruddin, S., Baggish, A.L., & Chen, A.A. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol, 15, 95(8), 948‒954.

Jordan, J., Birkenfeld, A.L., Melander, O., & Moro, C. (2018). Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk. Hypertension, 72, 270–276.

Baba, M., Yoshida, K., (2019). Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. Int J Mol Sci, 20(11), 2824.

McDonagh, T.A., Metra, M., Adamo, M., et al. (2021). 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J., 42(36), 3599‒3726.

Nadar, S., & Shaikh, M. (2019). Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev, 5, 1, 50–56.

Kang, S., Park, J.J., Choi, D., Yoon, C., & Oh, I. (2015). Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart, 101(23), 1881‒1888.

Fudim, M., Ambrosy, A., & Sun, J. (2018). High‐Sensitivity Troponin I in Hospitalized and Ambulatory Pa-tients with Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. Journal of the American Heart Association, 116, 1217–1220.

Thawabi, M., Hawatmeh, A., Studyvin, S., Habib, H., & Shamoon, F. (2017). Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovasc Diagn Ther, 7, 4, 359–366.

Zhu, Q., Xiao, W., Bai, Y., Ye, P., & Luo, L. (2016). The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population. Clin Interv Aging, 16, 11, 245‒253.

Rudolf, H., Mügge, A., Trampisch, H.J., Scharnagl, H., März, W., & Kara, K. (2020). NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study. Int J Cardiol Heart Vasc, 29, 100553.

Kitada, S., Kikuchi, S., Tsujino, T., Masuyama, T., & Ohte, N. (2018). The prognostic value of brain natriu-retic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub‐analysis of the J‐MELODIC study. ESC Heart Fail, 5(1), 36–45.

Omland, T., Sabatine, M.S., Jablonski, K.A., Rice, M.M., Hsia, J. et al. (2007). Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol, 50(3), 205‒14.

Liu, H., Cao, Y., Jin, J., Guo, Y., Zhu, C. et al. (2021). Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective co-hort study. Cardiovascular Diabetology, 20, 84.

Souza, T., Cerqueira, A.M., Suerdieck, J.G., de Sá, N.C., Sodré, G.S. et al. (2020). Prognostic Value of NT-proBNP versus Killip Classification in Patients with Acute Coronary Syndromes. Arq Bras Cardiol, 114(4), 666‒672.

He, W., Jiang, L., Chen, Y., Liu, Y., Chen, P., Duan, C., et al. (2021). The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study. BMC Cardiovascular Disorders, 21, 202.

Wang, L., Cong, H., Zhang, J., Hu, Y., & Li, X. (2021). Prognostic Significance of Preprocedural N-Terminal Pro-B-Type Natriuretic Peptide Assessment in Diabetic Patients with Multivessel Coronary Disease Undergoing Revas-cularization. Front. Cardiovasc. Med.

Zile, M.R., Claggett, B.L., Prescott, M.F., McMurra, J., & Packer, M. (2016). Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Heart Failure. J Am Coll Cardiol, 68(22), 2425‒2436.

Salah, K., Stienen, S., Pinto, Y.M., Eurlings, L.W., & Metra, M. (2019). Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart, 105(15), 1182–1189.

Savoia, C., Volpe, M., Alonzo, A., Rossi, C., & Rubattu, S. (2009). Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci (Lond), 118(4), 231‒240.

Santhekadur, P.K., Kumar, D.P., Seneshaw, M., Mirshahi F., & Sanyal, A.J. (2017). The multifaceted role of natriuretic peptides in metabolic syndrome. Biomed Pharmacother, 92, 826‒835.

Moyes, A.J., & Hobbs, A.J. (2019). C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci, 20(9), 2281.

Nakao, K., Kuwahara, K., Nishikimi, T., Nakagawa, Y., & Kinoshita, H. (2017). Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity. Hyperten-sion, 69, 286–296.

Gruden, G., Landi, A., & Bruno, G. (2014). Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research. Diabetes Care, 37(11), 2899‒2908.

Spannella, F., Giulietti F., Bordicchia M., Burnett J.C., & Sarzani R. (2019). Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. Scientific Reports, 9, 19178.

Birkenfeld, A., Budziarek, P., & Boschmann, M. (2008). Atrial Natriuretic Peptide Induces Postprandial Lipid Oxidation in Humans. Diabetes, 57, 12, 3199–3204.

Miyashita, K., Itoh, H., & Tsujimoto, H. (2009). Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity. Diabetes, 58, 12, 2880‒2892.

Tauscher, S., Nakagawa, H., & Völker, K. (2015). Role of atrial natriuretic peptide (ANP) in the regulation of insulin secretion and vitality of pancreatic ß cells. BMC Pharmacol Toxicol, 16, 1.

Undank, S., Kaiser, J., & Sikimic, J. (2017). Atrial Natriuretic Peptide Affects Stimulus-Secretion Coupling of Pancreatic β-Cells. Diabetes, 66, 11, 2840‒2848.

Welsh, P., & McMurray, J. (2012). B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia, 55, 1240–1243.

Coué, M., & Moro, C. (2015). Natriuretic peptide control of energy balance and glucose homeostasis. Bio-chimie, 124, 84‒91.

Maisel, A., Duran, J., & Wettersten, N. (2018). Natriuretic Peptides in Heart Failure Atrial and B-type Natriu-retic Peptides. Heart Failure Clin, 14, 13–25.

Sarzani, R., Spannella, F., & Giulietti, F. (2017). Cardiac Natriuretic Peptides, Hypertension and Cardiovascu-lar Risk. High Blood Press Cardiovasc Prev, 24, 2, 115–126.

Neeland, I., Winders, B., Ayers, & C., Das, S. (2013). Higher Natriuretic Peptide Levels Associate with a Fa-vorable Adipose Tissue Distribution Profile. JACC, 62, 8, 752–760.

Ramos, H., Birkenfeld, A., & de Bold, A. (2015). Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocrine Connection, 4, 25‒36.

De Almeida, J., Alves, C., & de Abreu, L. (2012). Involvement of the atrial natriuretic peptide in cardiovascu-lar pathophysiology and its relationship with exercise. Int Arch Med, 5, 4.

Khan, A., Cheng, S., & Magnusson, M. (2011). Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab, 96, 10, 3242-3249.

Malachias, M.V., Jhund, P.S., & Claggett, B.L. (2020). NT‐proBNP by Itself Predicts Death and Cardiovascu-lar Events in High‐Risk Patients with Type 2 Diabetes Mellitus. Journal of the American Heart Association, 9, 017462.

Coué, M., & Moro, C. (2015). Natriuretic peptide control of energy balance and glucose homeostasis. Bio-chimie, 124, 84‒91.

Villar, R., Becerra, A., & Alameda, C. (2012). Effects of acute hyperglycaemia on ANP levels in diabetic pa-tients. Endocrine Abstracts, 29, 677.

Cleasby, M. (2015). ANP-ing Up Diabetes: Impaired Natriuretic Peptide Action in Muscle Forms a Mechanis-tic Link Between Obesity and Diabetes. Diabetes, 64, 12, 3978‒3980.

Everett, B., Cook, N., & Chasman, D. A. (2013). Prospective Evaluation of B-type Natriuretic Peptide Con-centrations and the Risk of Type 2 Diabetes in Women. Clin Chem, 59, 3, 557–565.

Heinisch, B., Vila, G., & Resl, M. (2012). B-type natriuretic peptide (BNP) affects the initial response to in-travenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia, 55, 1400–1405.

Khan, A., Cheng, S., & Magnusson, M. (2011). Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab, 96, 10, 3242‒3249.

Rubattu, S., & Volpe, M. (2019). Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. Int J Mol Sci, 20, 16, 3991.

Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).

The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.

Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.